Lipid-lowering therapy is effective in reducing cardiovascular mortality and morbidity in people with PAD .
It may also improve local symptoms .
Until further evidence on the relative effectiveness of different lipid-lowering agents is available , use of a statin in people with PAD and a blood cholesterol level > /=3.5 mmol/litre is most indicated
BACKGROUND Lipid-lowering therapy is recommended for secondary prevention in people with coronary artery disease .
It may also reduce cardiovascular events and /or local disease progression in people with lower limb peripheral arterial disease ( PAD ) .
OBJECTIVES To assess the effects of lipid-lowering therapy on all-cause mortality , cardiovascular events and local disease progression in patients with PAD of the lower limb .
The Effectiveness of Glycosaminoglycans in Peripheral Vascular Disease Therapy: A Clinical and Experimental Trial
Thirty patients suffering from peripheral vascular disease ( stage – II according to Fontaine ) were included in a double-blind study aim ed at assessing the efficacy of a high-dose glycosaminoglycan ( GAG ) ( Sulodexide ) both in terms of laboratory parameters , such as lipid metabolism and blood coagulation components , and instrumental procedures ( strain-gauge plethysmography ) . Compared with the fifteen control patients ( treated with placebo ) , the fifteen patients treated with Sulodexide showed a signficant decrease in blood triglycerides and fibrinogen as well as a significantly increased HDL-cholesterol , and positive instrumental changes : at the end of treatment Peak and Rest Flow values – and consequently also Winsor 's index – were significantly increased only in patients treated with Sulodexide
Lipid-lowering therapy is effective in reducing cardiovascular mortality and morbidity in people with PAD .
It may also improve local symptoms .
Until further evidence on the relative effectiveness of different lipid-lowering agents is available , use of a statin in people with PAD and a blood cholesterol level > /=3.5 mmol/litre is most indicated
BACKGROUND Lipid-lowering therapy is recommended for secondary prevention in people with coronary artery disease .
It may also reduce cardiovascular events and /or local disease progression in people with lower limb peripheral arterial disease ( PAD ) .
OBJECTIVES To assess the effects of lipid-lowering therapy on all-cause mortality , cardiovascular events and local disease progression in patients with PAD of the lower limb .